A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations

Summary

The primary objective of this study is to determine the recommended dose and evaluate the effect of KW-6356 on motor symptoms in Parkinson's disease and the primary endpoint is the change from baseline in Movement disorder society-unified Parkinson's disease rating scale(MDS-UPDRS) partIII score between KW-6356 and placebo in patients with Parkinson's disease on treatment with Levodopa-containing preparations as an adjunctive therapy.

Timeline

Start

2018-09-29

Primary completion

2020-04-15

Completion

2020-04-15

Outcome

Met primary endpoint

release “announces today that the phase 2b study of KW-6356 in patients with Parkinson's disease on treatment with levodopa-containing preparations has met the primary endpoint.” kyowakirin.com ↗

Drugs

Indications